RedHill Biopharma Ltd. RDHL
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Growth
Revenue compounded at +5.0% a year over the five years to FY2024.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
The 10-year record
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | 0.0 | 0.0 | 0.1 | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Operating income $B | −0.0 | 0.0 | −0.0 | −0.1 | −0.1 | −0.0 | −0.0 | −0.1 | −0.0 | −0.0 |
| EBITDA $B | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ |
| Income tax $B | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ |
| Net income $B | −0.0 | 0.0 | −0.1 | −0.1 | −0.1 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| Free cash flow $B | −0.0 | −0.0 | −0.0 | −0.1 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| EPS, diluted $ | 0.00 | 0.01 | −0.12 | −0.21 | −0.21 | −0.14 | −0.17 | −0.26 | −0.24 | −0.19 |
| Dividend / sh $ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ |
| Payout % — not applicable: no dividend | — | — | — | — | — | — | — | — | — | — |
| ROE % | — | — | — | −859.7 | −206.2 | −76.1 | −80.7 | −84.5 | −47.8 | −35.1 |
Slide the table for earlier years. "—" not applicable · "◌" not available in our data.
Company facts, as filed
Reconciled in 10 of the 10 fiscal years we could check. 18 checks were skipped: the balance sheet is not tagged before 2016. 10 checks were skipped: cost of revenue is not tagged before 2017. Eight checks were skipped: EPS is not tagged before 2015.